GEN Exclusives

More »

GEN News Highlights

More »
May 3, 2012

Sartorius Inks Sales, Distribution Deal for C-LEcta’s Serratia Marcescens Nuclease

  • Sartorius Stedim Biotech negotiated worldwide sales and distribution rights to c-LEcta’s Serratia marcescens nuclease for biopharmaceutical applications. Under terms of the deal the customized endonuclease will be available as Denarase through all Sartorius Stedim Biotech’s sales channels.

    German firm c-LEcta specializes in the development of customized enzymes and production strains for industrial applications. The firm has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins.

    “This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance,” remarks  Uwe Gottschalk, Ph.D., vp of purification technologies at Sartorius Stedim Biotech. “The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry.” 

    Germany-based c-LEcta specializes in the development of customized enzymes and production strains for industrial applications. The firm applies patented technologies to enable the discovery and optimization of customized enzymes and microbial strains for the production of protein and small-molecule products. In January the firm achieved ISO 9001 certification, covering all operational areas from R&D to production and product sales. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?